C4 Therapeutics, Inc. (CCCC)
NASDAQ: CCCC · Real-Time Price · USD
3.490
+0.010 (0.29%)
Aug 3, 2026, 10:26 AM EDT - Market open
C4 Therapeutics Employees
C4 Therapeutics had 104 employees as of December 31, 2025. The number of employees decreased by 6 or -5.45% compared to the previous year.
Employees
104
Change (1Y)
-6
Growth (1Y)
-5.45%
Revenue / Employee
$335,202
Profits / Employee
-$998,087
Market Cap
385.88M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 104 | -6 | -5.45% |
| Dec 31, 2024 | 110 | -35 | -24.14% |
| Dec 31, 2023 | 145 | -1 | -0.68% |
| Dec 31, 2022 | 146 | 25 | 20.66% |
| Dec 31, 2021 | 121 | 22 | 22.22% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Autolus Therapeutics | 754 |
| Puma Biotechnology | 179 |
| Sutro Biopharma | 133 |
| Scribe Therapeutics | 89 |
| Editas Medicine | 87 |
| Century Therapeutics | 78 |
| Larimar Therapeutics | 71 |
| Atea Pharmaceuticals | 55 |
CCCC News
- 5 weeks ago - C4 Therapeutics Transcript: AGM 2026 - Transcripts
- 6 weeks ago - C4 Therapeutics Transcript: KOL event - Transcripts
- 6 weeks ago - C4 Therapeutics Slides: KOL event - Filings
- 7 weeks ago - C4 Therapeutics presents further analysis from cemsidomide trial - TheFly
- 7 weeks ago - C4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory Population - GlobeNewsWire
- 7 weeks ago - C4 Therapeutics Slides: Corporate presentation - Filings
- 2 months ago - C4 Therapeutics Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 2 months ago - C4 Therapeutics jumps after Bristol Myers myeloma data - TheFly